Approval · Notice of Compliance 14678 · 2013
VICTOZA: Notice of Compliance 14678
Issued August 23, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14678
- Date
- August 23, 2013
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: victoza is indicated for once-daily administration for the treatment of adults with type 2 diabetes to improve glycemic control in combination with metformin and a bsal insulin, when diet and exercise plus dual therapy with vitoza and metformin do not achieve adequate glycemic control
- Therapeutic class
- Human glucagon like peptide-1 (glp)1
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VICTOZA | Not yet assigned | — |
Medicinal ingredients
- LIRAGLUTIDE 6 MG per ML